MétaCan
Menu
Back to cohort
Record W4415752840 · doi:10.1016/j.metop.2025.100414

Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes

2025· article· en· W4415752840 on OpenAlexaff
Faisal A. Al-Harbi, Atheer M. Almutairi, Elan A. Aleidan, Ghaida S. Alabdulaaly, Ahmed Y. Azzam

Bibliographic record

VenueMetabolism Open · 2025
Typearticle
Languageen
FieldMathematics
TopicStatistical Methods in Clinical Trials
Canadian institutionsArtificial Intelligence in Medicine (Canada)
Fundersnot available
KeywordsEmulationType 2 diabetesClinical trialDiabetes mellitusConfidence intervalObesityInterval (graph theory)

Abstract

fetched live from OpenAlex

Amylin-pathway therapies represent a novel therapeutic class for obesity and type 2 diabetes, however head-to-head comparative data and long-term outcome predictions remain limited. We conducted target trial emulation and computational predictive modeling aiming to predict future trial outcomes and comparative effectiveness across the amylin-pathway development program. Following PRISMA 2020 and TARGET framework guidelines, we search in the current literature for eligible trials and extracted data from seven randomized controlled trials (N=5,786 participants) of amylin-pathway therapies published up to September 2025. We reconstructed high-precision synthetic individual patient data (IPD) and developed computational models for virtual head-to-head comparisons, dose-response optimization, longitudinal trajectory prediction, and trial simulation. Network meta-analysis integrated evidence across CagriSema, cagrilintide, and amycretin formulations. Synthetic IPD reconstruction achieved >99% fidelity to source trials, validated through leave-trial-out cross-validation (efficacy RMSE: 2.9% points, calibration slope: 0.61; discontinuation RMSE: 0.18, slope: 1.08). Virtual head-to-head modeling confirmed CagriSema superiority over amycretin subcutaneous at matched timepoints (posterior probability >0.95). Dose-response modeling identified optimal amycretin exposures (ED80: 8.88 mg subcutaneous, 95% CI: 7.12-11.08), with benefit-risk frontier analysis delineating a therapeutic window at 10-20 mg balancing efficacy plateau against tolerability thresholds (GI-AE <75%, discontinuation <20%). Longitudinal kinetics showed plateau timing at 52-68 weeks for obesity outcomes and 24-32 weeks for glycemic endpoints. Heterogeneity analysis revealed complete resolution for GI adverse events (I 2 _DL = 0%, τ 2 = 0) and moderate variation for discontinuation (I 2 _DL = 13%, τ 2 = 0.03) after logit-scale correction with proper within-arm variance weighting. Machine learning models predicted treatment response with 82-87% accuracy using baseline characteristics. Synthetic target trial emulation with structured validation (leave-trial-out, posterior predictive checks, simulation-based calibration) demonstrated promising evidence for amylin-pathway development optimization. Benefit-risk frontier analysis identified an optimal 10-20 mg subcutaneous therapeutic window, and heterogeneity quantification through maximum a posteriori (MAP) predictive interval provides design-ready estimates for confirmatory trials requiring around 800-1,200 participants per arm for 90% power.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.034
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: Theoretical or conceptual
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.116
Threshold uncertainty score0.974

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.034
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.311
GPT teacher head0.499
Teacher spread0.188 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designTheoretical or conceptual
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueMetabolism OpenSame topicStatistical Methods in Clinical TrialsFrench-language works237,207